AngioDynamics (NASDAQ:ANGO) CEO James Clemmer Purchases 10,000 Shares of Stock

AngioDynamics, Inc. (NASDAQ:ANGO) CEO James Clemmer acquired 10,000 shares of AngioDynamics stock in a transaction that occurred on Thursday, October 9th. The shares were purchased at an average cost of $11.15 per share, for a total transaction of $111,500.00. Following the purchase, the chief executive officer directly owned 882,529 shares in the company, valued at $9,840,198.35. The trade was a 1.15% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

AngioDynamics Price Performance

AngioDynamics stock opened at $11.14 on Friday. The company’s 50 day simple moving average is $10.11 and its 200 day simple moving average is $9.79. AngioDynamics, Inc. has a fifty-two week low of $5.99 and a fifty-two week high of $13.50. The firm has a market capitalization of $458.97 million, a price-to-earnings ratio of -14.28 and a beta of 0.78.

AngioDynamics (NASDAQ:ANGO) last announced its earnings results on Thursday, October 2nd. The medical instruments supplier reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.02. The firm had revenue of $75.71 million for the quarter, compared to the consensus estimate of $72.69 million. AngioDynamics had a negative net margin of 10.67% and a negative return on equity of 3.16%. The business’s quarterly revenue was up 12.1% on a year-over-year basis. During the same period last year, the company posted ($0.11) EPS. AngioDynamics has set its FY 2026 guidance at -0.330–0.230 EPS. As a group, analysts predict that AngioDynamics, Inc. will post -0.37 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on ANGO. HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of AngioDynamics in a research note on Wednesday, July 16th. Canaccord Genuity Group raised their target price on shares of AngioDynamics from $17.00 to $18.00 and gave the company a “buy” rating in a research note on Friday, October 3rd. Wall Street Zen cut shares of AngioDynamics from a “buy” rating to a “hold” rating in a research note on Saturday, October 4th. Lake Street Capital began coverage on shares of AngioDynamics in a research note on Wednesday, July 16th. They issued a “buy” rating and a $24.00 target price for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a research note on Wednesday. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $19.33.

Institutional Investors Weigh In On AngioDynamics

Institutional investors have recently modified their holdings of the business. GAMMA Investing LLC raised its stake in AngioDynamics by 1,281.4% in the first quarter. GAMMA Investing LLC now owns 13,897 shares of the medical instruments supplier’s stock valued at $130,000 after purchasing an additional 12,891 shares in the last quarter. Acuitas Investments LLC raised its stake in AngioDynamics by 9.7% in the first quarter. Acuitas Investments LLC now owns 442,230 shares of the medical instruments supplier’s stock valued at $4,153,000 after purchasing an additional 38,950 shares in the last quarter. Principal Financial Group Inc. raised its stake in AngioDynamics by 25.1% in the first quarter. Principal Financial Group Inc. now owns 120,008 shares of the medical instruments supplier’s stock valued at $1,127,000 after purchasing an additional 24,047 shares in the last quarter. Cornerstone Investment Partners LLC acquired a new position in AngioDynamics in the first quarter valued at about $169,000. Finally, Cerity Partners LLC raised its stake in AngioDynamics by 22.0% in the first quarter. Cerity Partners LLC now owns 12,929 shares of the medical instruments supplier’s stock valued at $121,000 after purchasing an additional 2,333 shares in the last quarter. Institutional investors own 89.43% of the company’s stock.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.